Publications & Review Indexing

Publication Policy and Literature Review Index

BioTech Pharma Research Institute · Editorial Office · Current as of March 2025

Editorial Workflow

The development of each literature review proceeds through five stages. The first is scoping, in which the editorial board defines the analytical questions a review must address: molecular characterization, receptor pharmacology, mechanisms of action, preclinical evidence, clinical evidence, safety, regulatory status, and methodological limitations. The second is retrieval, in which structured searches are run against PubMed, Web of Science, and Scopus using validated search strings combining peptide-specific terms with mechanism, methodology, and outcome descriptors. The third is screening, in which retrieved records are evaluated for relevance, methodological soundness, and substantive contribution to the analytical questions defined at scoping.

The fourth stage is synthesis, in which extracted data are integrated into the narrative review structure with explicit attention to evidence weighting, conflicting findings, and methodological caveats. The fifth and final stage is peer verification, in which an independent reviewer with relevant expertise reviews the draft for accuracy, balance, and methodological honesty. Reviews are not published until peer verification is complete; corrections identified during verification are implemented prior to publication, with substantive editorial disagreements escalated to the full editorial board.

Citation Policy

All factual and mechanistic claims are supported by reference to peer-reviewed primary literature, identified by PubMed identifier (PMID) wherever available and supplemented by Digital Object Identifier (DOI) or journal-issued persistent identifier where appropriate. Reference lists at the end of each review follow numbered-citation conventions consistent with biomedical publication style; in-text citations are anchored to entries in the reference list via intra-document links, permitting direct navigation between citation and source.

The Institute applies a minimum citation density of approximately three to five references per thousand words of analytical text, with substantially higher density in mechanism-of-action sections, sections discussing controversial findings, and sections summarizing clinical evidence. Where claims rest on a single primary source, we say so; where claims are supported by converging evidence from multiple independent investigators, we describe the breadth of the supporting literature. Where claims rest on preclinical evidence alone, the limitations of extrapolating to human populations are made explicit.

Hyperlinks to PubMed records are provided in the reference list as a convenience to readers; the Institute does not control the operation of external databases and cannot guarantee that linked records will remain accessible indefinitely. Readers are advised to record PMIDs directly when conducting their own literature work, rather than relying on hyperlinks alone.

Versioning and Revision History

Published reviews are dated at the time of original publication and are revised periodically as the underlying primary literature evolves. Revision triggers include: publication of substantial new primary evidence (particularly randomized trial data); identification of methodological errors in previously cited studies (e.g., retractions or expressions of concern); regulatory developments (such as approval or withdrawal status changes); and reader-submitted correction requests that survive editorial review.

Substantive revisions are noted in the "last revised" line at the head of each review. Minor corrections (typographical errors, broken external links) are made without explicit annotation. Major revisions that materially change the analytical conclusions of a review are accompanied by a brief revision note describing the nature of the change. The Institute does not maintain a publicly accessible diff archive of previous versions; researchers requiring access to historical versions for systematic review or citation purposes should contact the editorial office.

Currently Published Reviews

The database currently contains 27 published literature reviews, organized below by therapeutic category. Each entry links to the full review and indicates the principal mechanism category covered.

Growth Hormone Secretagogues

• Ipamorelin — selective GHS-R1a agonist; minimal cortisol/prolactin elevation
• Hexarelin — GHS-R1a agonist with documented cardioprotective signals
• GHRP-2 (Pralmorelin) — clinically validated growth hormone secretagogue
• GHRP-6 — first-generation GHRP with appetite-stimulating activity

GHRH Analogs

• Sermorelin — GHRH(1-29) fragment, clinical use in growth hormone deficiency
• CJC-1295 — DAC-modified GHRH analog with extended half-life
• Tesamorelin — FDA-approved for HIV-associated lipodystrophy

Tissue Repair and Regenerative Peptides

• BPC-157 — pentadecapeptide; extensive preclinical evidence in tissue healing
• TB-500 (Thymosin Beta-4 fragment) — actin sequestration, angiogenesis
• Thymosin Beta-4 — full-length parent peptide; regenerative medicine
• GHK-Cu — copper tripeptide; collagen synthesis, wound healing
• Mechano Growth Factor (MGF) — IGF-1 splice variant; satellite cell activation

Neuropeptides and Nootropics

• Cerebrolysin — peptide preparation; neurotrophic-like effects in stroke and dementia
• Semax — ACTH(4-10) derivative; cognitive enhancement, stroke neuroprotection
• Selank — tuftsin analog; anxiolytic, GABAergic modulation
• DSIP (Delta Sleep-Inducing Peptide) — sleep regulation, neuroprotection

Immunomodulatory and Antimicrobial Peptides

• Thymosin Alpha-1 — T-cell maturation; approved for hepatitis B/C in multiple jurisdictions
• Thymalin — thymic peptide complex; immunomodulation in aging
• KPV (Lys-Pro-Val) — melanocortin-derived anti-inflammatory tripeptide
• LL-37 (Cathelicidin) — antimicrobial, immune modulation, wound healing

Reproductive and Endocrine Peptides

• Kisspeptin — GnRH regulation, reproductive endocrinology, puberty
• Triptorelin — GnRH agonist; prostate cancer, endometriosis

Melanocortin Receptor Agonists

• PT-141 (Bremelanotide) — FDA-approved for hypoactive sexual desire disorder
• Melanotan-2 — melanocortin agonist; pigmentation pharmacology

Mitochondrial and Longevity Peptides

• MOTS-c — mitochondrial-derived peptide; metabolic regulation
• Epithalon — telomerase activation, pineal regulation

Peptide Hormones

• Vasopressin — antidiuretic and vasopressor pharmacology, critical care applications

Forthcoming Reviews

The editorial board maintains a working list of compounds under active scoping for future inclusion. Inclusion in the working list does not commit the Institute to publication on a specific timeline; publication proceeds only after sufficient primary literature accumulates to support a substantive review and after the editorial workflow described above has been completed. Researchers wishing to suggest compounds for prioritization may submit proposals via the editorial office.

Use in Research

The complete site index, including all 27 literature reviews and ancillary editorial pages, is available on the site map. Researchers using automated literature-discovery tools may consult the machine-readable XML sitemap at /sitemap.xml.